Target type: biologicalprocess
Any process that stops, prevents, or reduces the frequency, rate or extent of ferroptosis. [GOC:sp, PMID:24439385, PMID:25402683, PMID:29290465]
Negative regulation of ferroptosis is a complex cellular process that counteracts the iron-dependent form of programmed cell death known as ferroptosis. This process is essential for maintaining cellular homeostasis and preventing excessive cell death. Key mechanisms involved in negative regulation of ferroptosis include:
1. **Lipid peroxidation inhibition:** Ferroptosis is driven by the accumulation of lipid peroxidation products in cell membranes. This process is inhibited by enzymes like glutathione peroxidase 4 (GPX4), which reduces lipid hydroperoxides to their corresponding alcohols, thus preventing the formation of reactive oxygen species (ROS) and mitigating membrane damage.
2. **Iron metabolism regulation:** Iron is crucial for ferroptosis, as it serves as a catalyst for the generation of ROS. Negative regulation involves mechanisms that control iron availability, including:
* **Ferritin:** This protein binds and sequesters iron, preventing its participation in ROS formation.
* **Hepcidin:** This hormone regulates iron absorption in the intestine and iron release from macrophages.
* **Transferrin:** This protein binds iron in the blood, reducing its accessibility for Fenton reactions that generate ROS.
3. **Antioxidant defense:** Cells employ various antioxidant mechanisms to counteract oxidative stress and prevent ferroptosis. These include:
* **Glutathione:** This tripeptide acts as a reducing agent and is crucial for GPX4 activity.
* **NADPH:** This cofactor is essential for the regeneration of reduced glutathione, maintaining its antioxidant capacity.
* **Other antioxidant enzymes:** Superoxide dismutase (SOD) and catalase are involved in the detoxification of ROS.
4. **Autophagy:** This cellular process removes damaged organelles, including mitochondria, which are major sources of iron and ROS. Autophagy contributes to the clearance of lipid peroxidation products and the reduction of ferroptosis susceptibility.
5. **Signaling pathways:** Multiple signaling pathways regulate ferroptosis, including:
* **p53 pathway:** p53 activation can induce the expression of genes involved in ferroptosis suppression, such as GPX4.
* **NF-κB pathway:** NF-κB activation can promote the expression of antioxidant genes, contributing to ferroptosis resistance.
6. **Other mechanisms:**
* **Coenzyme Q10:** This lipid-soluble antioxidant can protect against lipid peroxidation.
* **Lipoic acid:** This antioxidant can scavenge ROS and contribute to ferroptosis suppression.
7. **Regulation of lipid metabolism:** Ferroptosis is influenced by the composition of cell membranes. The regulation of lipid biosynthesis and degradation can impact the susceptibility to ferroptosis.
Negative regulation of ferroptosis is a complex and tightly regulated process involving multiple cellular pathways and mechanisms. This intricate balance is essential for maintaining cellular health and preventing excessive cell death in response to various stresses.'
"
| Protein | Definition | Taxonomy |
|---|---|---|
| Cystine/glutamate transporter | A cystine/glutamate transporter that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q9UPY5] | Homo sapiens (human) |
| Nuclear factor erythroid 2-related factor 2 | A nuclear factor erythroid 2-related factor 2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q16236] | Homo sapiens (human) |
| Phospholipid hydroperoxide glutathione peroxidase | A phospholipid hydroperoxide glutathione peroxidase GPX4 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P36969] | Homo sapiens (human) |
| NAD | An NAD(P)H dehydrogenase [quinone] 1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P15559] | Homo sapiens (human) |
| Compound | Definition | Classes | Roles |
|---|---|---|---|
| melatonin | acetamides; tryptamines | anticonvulsant; central nervous system depressant; geroprotector; hormone; human metabolite; immunological adjuvant; mouse metabolite; radical scavenger | |
| 4'-bromoflavone | 4'-bromoflavone: structure in first source | ||
| beta-naphthoflavone | beta-naphthoflavone : An extended flavonoid resulting from the formal fusion of a benzene ring with the f side of flavone. beta-Naphthoflavone: A polyaromatic hydrocarbon inducer of P4501A1 and P4501A2 cytochromes. (Proc Soc Exp Biol Med 1994 Dec:207(3):302-308) | extended flavonoid; naphtho-gamma-pyrone; organic heterotricyclic compound | aryl hydrocarbon receptor agonist |
| beta-lapachone | beta-lapachone : A benzochromenone that is 3,4-dihydro-2H-benzo[h]chromene-5,6-dione substituted by geminal methyl groups at position 2. Isolated from Tabebuia avellanedae, it exhibits antineoplastic and anti-inflammatory activities. beta-lapachone: antineoplastic inhibitor of reverse transcriptase, DNA topoisomerase, and DNA polymerase | benzochromenone; orthoquinones | anti-inflammatory agent; antineoplastic agent; plant metabolite |
| vitamin k 3 | Vitamin K 3: A synthetic naphthoquinone without the isoprenoid side chain and biological activity, but can be converted to active vitamin K2, menaquinone, after alkylation in vivo. | 1,4-naphthoquinones; vitamin K | angiogenesis inhibitor; antineoplastic agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; human urinary metabolite; nutraceutical |
| mesalamine | mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position. Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed) | amino acid; aromatic amine; monocarboxylic acid; monohydroxybenzoic acid; phenols | non-steroidal anti-inflammatory drug |
| sulfapyridine | sulfapyridine : A sulfonamide consisting of pyridine with a 4-aminobenzenesulfonamido group at the 2-position. Sulfapyridine: Antibacterial, potentially toxic, used to treat certain skin diseases. | pyridines; substituted aniline; sulfonamide; sulfonamide antibiotic | antiinfective agent; dermatologic drug; drug allergen; environmental contaminant; xenobiotic |
| sulfasalazine | sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position. Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907) | ||
| sulforaphane | sulforaphane : An isothiocyanate having a 4-(methylsulfinyl)butyl group attached to the nitrogen. sulforaphane: from Cardaria draba L. | isothiocyanate; sulfoxide | antineoplastic agent; antioxidant; EC 3.5.1.98 (histone deacetylase) inhibitor; plant metabolite |
| cysteine | cysteine; cysteine zwitterion; L-alpha-amino acid; proteinogenic amino acid; serine family amino acid | EC 4.3.1.3 (histidine ammonia-lyase) inhibitor; flour treatment agent; human metabolite | |
| dimethylformamide | Dimethylformamide: A formamide in which the amino hydrogens are replaced by methyl groups. N,N-dimethylformamide : A member of the class of formamides that is formamide in which the amino hydrogens are replaced by methyl groups. | formamides; volatile organic compound | geroprotector; hepatotoxic agent; polar aprotic solvent |
| iberin | isothiocyanate; sulfoxide | apoptosis inducer; plant metabolite; quorum sensing inhibitor | |
| oleanolic acid | hydroxy monocarboxylic acid; pentacyclic triterpenoid | plant metabolite | |
| 2-tert-butylhydroquinone | 2-tert-butylhydroquinone : A member of the class of hydroquinones in which one of the ring hydrogens of hydroquinone is replaced by a tert-butyl group. 2-tert-butylhydroquinone: an anticarcinogenic and chemopreventive agent | hydroquinones | food antioxidant |
| quisqualic acid | Quisqualic Acid: An agonist at two subsets of excitatory amino acid receptors, ionotropic receptors that directly control membrane channels and metabotropic receptors that indirectly mediate calcium mobilization from intracellular stores. The compound is obtained from the seeds and fruit of Quisqualis chinensis. | non-proteinogenic alpha-amino acid | |
| brusatol | brusatol: quassinoid from B. javanica; structure | triterpenoid | |
| hei 712 | organofluorine compound; quinolone | ||
| c 1303 | C 1303: DNa-binding drug; structure given indicates that the cpd should be the dimethylamino cpd, but it is named as the diethylamino cpd | ||
| serine o-sulfate | L-serine O-sulfate : A non-proteinogenic L-alpha-amino acid that is the O-sulfo derivative of L-serine. serine O-sulfate: RN given refers to (L)-isomer | L-serine derivative; non-proteinogenic L-alpha-amino acid; O-sulfoamino acid | |
| homocysteic acid | homocysteic acid : A non-proteinogenic alpha-amino acid that is homocysteine in which the thiol group has benn oxidised to the corresponding sulfonic acid. homocysteic acid: promotes growth in hypophysectomized rats; RN given refers to parent cpd L-homocysteic acid : A homocysteic acid with L-configuration. | homocysteic acid | NMDA receptor agonist |
| 2-(5-Chlorobenzo[b]thiophen-3-yl)acetic acid | 1-benzothiophenes | ||
| alyssin | sulfoxide | ||
| nsc 366140 | NSC 366140: a 9-methoxypyrazoloacridine; structure given in first source | ||
| bardoxolone methyl | methyl 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate: structure in first source | cyclohexenones | |
| resveratrol | trans-resveratrol : A resveratrol in which the double bond has E configuration. | resveratrol | antioxidant; phytoalexin; plant metabolite; quorum sensing inhibitor; radical scavenger |
| dimethyl fumarate | diester; enoate ester; methyl ester | antipsoriatic; immunomodulator | |
| (1e,4e)-1,5-bis(2-methoxyphenyl)penta-1,4-dien-3-one | |||
| curcumin | curcumin : A beta-diketone that is methane in which two of the hydrogens are substituted by feruloyl groups. A natural dyestuff found in the root of Curcuma longa. Curcumin: A yellow-orange dye obtained from tumeric, the powdered root of CURCUMA longa. It is used in the preparation of curcuma paper and the detection of boron. Curcumin appears to possess a spectrum of pharmacological properties, due primarily to its inhibitory effects on metabolic enzymes. | aromatic ether; beta-diketone; diarylheptanoid; enone; polyphenol | anti-inflammatory agent; antifungal agent; antineoplastic agent; biological pigment; contraceptive drug; dye; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor; EC 1.8.1.9 (thioredoxin reductase) inhibitor; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; flavouring agent; food colouring; geroprotector; hepatoprotective agent; immunomodulator; iron chelator; ligand; lipoxygenase inhibitor; metabolite; neuroprotective agent; nutraceutical; radical scavenger |
| umi-77 | UMI-77: an Mcl-1 inhibitor; structure in first source | ||
| 2-chloro-N-heptyl-N-(3-methylphenyl)acetamide | anilide | ||
| 2,6-bis(2,5-dimethoxybenzylidene)cyclohexanone | 2,6-bis(2,5-dimethoxybenzylidene)cyclohexanone: an anti-inflammatory agent that down-regulates cyclooxygenase-2 expression; structure in first source | ||
| N-(1,3-benzodioxol-5-yl)-2-chloro-N-[(2-prop-2-enoxyphenyl)methyl]acetamide | benzodioxoles | ||
| susalimod | susalimod: analogue of sulphasalazine, was designed for use in the treatment of rheumatoid arthritis | ||
| ML162 | ML162 : A monochlorobenzene that is benzene substituted by (chloroacetyl){2-oxo-2-[(2-phenylethyl)amino]-1-(thiophen-2-yl)ethyl}amino, chloro and methoxy groups at positions 1, 3 and 4, respectively. It is a covalent inhibitor of glutathione peroxidase 4 (GPX4) that induces ferroptosis in cells. | monochlorobenzenes; monomethoxybenzene; organochlorine compound; secondary carboxamide; tertiary carboxamide; thiophenes | EC 1.11.1.9 (glutathione peroxidase) inhibitor; ferroptosis inducer |
| 5-methoxy-1,2-dimethyl-3-((4-nitrophenoxy)methyl)indole-4,7-dione | 5-methoxy-1,2-dimethyl-3-((4-nitrophenoxy)methyl)indole-4,7-dione: structure in first source | ||
| strigol | strigol : A strigolactone in which the tricyclic lactone moiety bears a hydroxy substitutuent at the position para to the gem-dimethyl group. strigol: a strigolactone from roots of various PLANTS; it stimulates seed germination of parasitic STRIGA and OROBANCHE; structure in first source | indenofuran; secondary alcohol; strigolactone | |
| bisantrene | |||
| 4,3',5'-tri-o-methylpiceatannol | |||
| hylin | |||
| 6-methylsulfinylhexyl isothiocyanate | 6-(Methylsulfinyl)hexyl isothiocyanate: showed a dose-dependent inhibition of LPS-induced nitric oxide (NO), iNOS mRNA and protein. | sulfoxide | |
| memoquin | memoquin: structure in first source | ||
| dimethoxycurcumin | dimethoxycurcumin: has antineoplsatic activity; structure in first source | ||
| erastin | erastin : A member of the class of quinazolines that is quinazolin-4(3H)-one in which the hydrogens at positions 2 and 3 are replaced by 1-{4-[(4-chlorophenoxy)acetyl]piperazin-1-yl}ethyl and 2-ethoxyphenyl groups, respectively. It is an inhibitor of voltage-dependent anion-selective channels (VDAC2 and VDAC3) and a potent ferroptosis inducer. erastin: an antineoplastic agent; structure in first source | aromatic ether; diether; monochlorobenzenes; N-acylpiperazine; N-alkylpiperazine; quinazolines; tertiary carboxamide | antineoplastic agent; ferroptosis inducer; voltage-dependent anion channel inhibitor |
| ML-210 | ML-210 : An N-acylpiperazine that is piperazine substituted by 5-methyl-4-nitro-1,2-oxazole-3-carbonyl and bis(4-chlorophenyl)methyl groups at positions 1 and 4, respectively. It is a glutathione peroxidase 4 (GPX4) inhibitor which induces ferroptosis in cancer cells expressing the RAS oncogene. | C-nitro compound; diarylmethane; isoxazoles; monochlorobenzenes; N-acylpiperazine; N-alkylpiperazine; tertiary carboxamide | antineoplastic agent; EC 1.11.1.9 (glutathione peroxidase) inhibitor; ferroptosis inducer; prodrug |
| dicumarol | Dicumarol: An oral anticoagulant that interferes with the metabolism of vitamin K. It is also used in biochemical experiments as an inhibitor of reductases. | hydroxycoumarin | anticoagulant; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor; Hsp90 inhibitor; vitamin K antagonist |
| ethyl biscoumacetate | Ethyl Biscoumacetate: A coumarin that is used as an anticoagulant. It has actions similar to those of WARFARIN. (From Martindale, The Extra Pharmacopoeia, 30th ed, p226) | hydroxycoumarin | |
| nsc 158393 | NSC 158393: structure given in first source | ||
| (1S,2R)-2-[[(1S)-1-[(1,3-dioxo-2-isoindolyl)methyl]-3,4-dihydro-1H-isoquinolin-2-yl]-oxomethyl]-1-cyclohexanecarboxylic acid | LH601A: inhibits the interaction between KEAP1 and NRF2; structure in first source | phthalimides |